Pfizer Ltd (PFIZER) — shareholding pattern, promoter holding, financials and share price
About Pfizer Ltd (PFIZER)
Pfizer Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as PFIZER and on the BSE under scrip code 500680. Its ISIN is INE182A01018.
Pfizer Ltd is engaged in manufacturing, marketing, trading and export of pharmaceutical products. It manufactures products through its own facility and also has various independent contract/ third party manufacturers based across the country and sells its products through independent distributors primarily in India. [1] It is the 3rd largest multinational pharmaceutical company in India. [2]
Pfizer Limited is a major pharmaceutical company involved in the manufacture, marketing, and export of a range of pharmaceutical products, including specialized medicines across 15 therapeutic areas. It operates manufacturing facilities in Goa and Thane, contributing to its extensive global footprint with 43 facilities worldwide.
The company has a rich history in India dating back to 1950, being the first to introduce clinical research in the country. It has evolved through strategic mergers and collaboration, most recently merging with Wyeth Limited and divesting several older product lines.
Listed peers in Pharmaceuticals: Rubicon Research Ltd, Piramal Pharma Ltd, Granules India Ltd, Astrazeneca Pharma India Ltd, ERIS Lifesciences Ltd, Caplin Point Laboratories Ltd.
Valuation & Returns
10 Jul 2026At ₹4,740 a share on 10 Jul 2026, Pfizer Ltd (PFIZER) was valued at a price-to-earnings ratio of 30.02x against an industry P/E of 36.41x and a price-to-book of 5.14x on a book value of ₹921.88 per share as of Mar 2025. Solomo computes return on equity of 17.13% and return on capital employed of 23.14% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 30.02x
- Industry P/E
- 36.41x
- P/B
- 5.14x
- EPS (TTM)
- ₹157.92
- Book value / share
- ₹921.88
- ROE
- 17.13%
- ROCE
- 23.14%
- ROA
- 14.71%
- Debt / equity
- 0.01x
- Dividend yield
- 3.48%
- EBITDA margin
- 41.39%
- 52-week range
- ₹4,361 – ₹5,878.55
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Nov 2008In the year ended Nov 2008, Pfizer Ltd (PFIZER) reported revenue of ₹678 crore, net profit of ₹300 crore and earnings per share of ₹100.39. That compares with revenue of ₹676 crore and net profit of ₹340 crore in Nov 2007. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹629 crore and net profit ₹200 crore (standalone).
| Metric | Nov 2006 | Nov 2007 | Nov 2008 |
|---|---|---|---|
| Revenue (₹ cr) | 664 | 676 | 678 |
| Net profit (₹ cr) | 106 | 340 | 300 |
| EPS (₹) | 35.64 | 113.94 | 100.39 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 0.93% | 1.18% | -4.40% | -0.43% |
| Profit growth | 14.74% | 8.56% | 7.81% | -11.89% |
| Stock price CAGR | 9% | -4% | 7% | -12% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 63.92% of Pfizer Ltd (PFIZER) (unchanged from the previous quarter), foreign institutional investors (FII) hold 1.65% and domestic institutional investors (DII) hold 17.8%. Market capitalisation was ₹21,684 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: NIPPON LIFE INDIA TRUSTEE LTD 4.17%, LIFE INSURANCE CORPORATION OF INDIA 3.74%, ICICI PRUDENTIAL FUND 3.31%, QUANT MUTUAL FUND 2.22%, Atul Limited 2.1%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 63.92% | - | 1.65% | 17.8% | 36.08% |
| Mar 2026 | 63.92% | - | 2.81% | 16.89% | 36.08% |
| Dec 2025 | 63.92% | - | 2.71% | 17.05% | 36.08% |
| Sep 2025 | 63.92% | - | 2.6% | 17.1% | 36.08% |
| Jun 2025 | 63.92% | - | 2.39% | 17.23% | 36.08% |
| Mar 2025 | 63.92% | - | 2.18% | 17.1% | 36.08% |
| Dec 2024 | 63.92% | - | 2.75% | 16.79% | 36.08% |
| Sep 2024 | 63.92% | - | 3.54% | 16.03% | 36.08% |